Canavan Disease (ASPA-Related Leukodystrophy)
A rare inherited leukodystrophy caused by aspartoacylase enzyme deficiency, leading to progressive loss of white matter and developmental regression, most often presenting in infancy.
- Confirmed by urine NAA and ASPA testing
- Lifelong supportive care needs
- Active gene therapy research
- Inheritance Pattern
- Autosomal Recessive
- Gene Involved
- ASPA
- Typical Onset
- Infancy (Classic Form)
- Key Research Area
- AAV-Mediated ASPA Gene Therapy
Condition Overview
Canavan disease is a rare, inherited leukodystrophy caused by mutations in the ASPA gene, which encodes the enzyme aspartoacylase. This enzyme normally breaks down N-acetylaspartate (NAA), a molecule produced in neurons. When aspartoacylase activity is deficient, NAA accumulates abnormally in the brain, disrupting the normal development and maintenance of myelin, the fatty insulation that allows nerve cells to communicate efficiently.
The result is progressive spongy degeneration of brain white matter, most commonly presenting in early infancy with macrocephaly, severe hypotonia (low muscle tone), and developmental delay that often evolves into significant developmental regression. A milder, later-onset form exists but is less common.
Canavan disease is most prevalent in certain founder populations, including individuals of Ashkenazi Jewish descent, where carrier screening programs are well established, though it can occur in any population. Diagnosis relies on elevated urinary N-acetylaspartate and confirmatory ASPA genetic testing.
Types and Subtypes
Canavan disease is generally divided by severity and age of onset, though the classic infantile form is by far the most common presentation.
Symptoms and Signs
Symptoms in classic Canavan disease typically appear within the first few months of life and progressively worsen over time.
Causes and Risk Factors
Canavan disease results entirely from inherited ASPA gene mutations rather than from environmental or lifestyle factors.
Diagnosis and Investigations
Diagnosis combines a biochemical urine test with confirmatory genetic testing and supportive imaging.
Disease Severity and Risk Stratification
Canavan disease is not staged like a cancer; severity is generally categorized by the classic versus milder juvenile-onset presentation.
Standard Treatment Options
There is no treatment that reverses the underlying enzyme deficiency outside of investigational gene therapy, so standard care is supportive and aimed at maximizing comfort and function.
Advanced and Emerging Therapies
Canavan disease is among the leukodystrophies furthest along in gene therapy development, reflecting its well-defined single-gene cause.
Gene Therapy
AAV-Mediated ASPA Gene Replacement
Investigational gene therapy approaches deliver a functional copy of the ASPA gene directly into the brain using adeno-associated viral vectors, currently being evaluated in clinical trials.
Symptom-Directed Care
Multidisciplinary Supportive Management
Coordinated neurology, feeding, physical therapy, and respiratory support remains the standard of care outside of clinical trials.
Research Direction
Enzyme Replacement and Substrate-Reduction Approaches
Earlier-stage research has also explored direct enzyme delivery and approaches to reduce NAA production, though gene therapy is the most advanced avenue.
Biomarkers and Precision Medicine
Biochemical and genetic markers are central to diagnosis and to monitoring disease and treatment response.
When a Second Opinion May Be Important
Because Canavan disease is rare, specialist neurogenetics input is valuable for confirming diagnosis and exploring research options.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Classic Canavan disease is typically associated with significant lifelong disability, while the milder juvenile-onset form tends to follow a slower course. Ongoing gene therapy research may meaningfully change the outlook for future patients.
Supportive Care and Living with Canavan Disease
Living with Canavan disease centers on coordinated multidisciplinary care to support comfort, nutrition, and function over time.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families affected by Canavan disease get medical report review, coordinate second opinions with neurogenetics specialists, and access information on gene therapy clinical trials.
Get a free case reviewFrequently Asked Questions
Canavan disease is a rare inherited leukodystrophy caused by ASPA gene mutations that lead to deficient aspartoacylase enzyme activity and progressive brain white matter degeneration.
Early signs in classic disease often include an unusually large head size, poor head control, severe low muscle tone, and developmental delay in the first months of life.
Yes, it follows an autosomal recessive inheritance pattern, meaning a child must inherit an altered ASPA gene copy from each parent.
Diagnosis typically combines an elevated urine N-acetylaspartate (NAA) level with confirmatory ASPA genetic testing and supportive brain MRI findings.
There is no cure currently available, but gene therapy approaches aiming to deliver a working ASPA gene are being studied in clinical trials.
Certain ASPA founder variants are more common in individuals of Ashkenazi Jewish descent, though the disease can occur in any population.
Yes, a rarer juvenile-onset form exists with later onset and a generally slower course than the classic infantile form.
Care typically involves pediatric neurology, neurogenetics, physical and speech therapy, and nutrition specialists working together.
Yes, gene therapy clinical trials are underway, and eligibility can be discussed with a specialist center experienced in leukodystrophies.
Yes. CancerFax can help families obtain medical report review, coordinate second opinions with neurogenetics specialists, and explore access to gene therapy clinical trials and supportive care resources.